Bellevue Group Ag Bei Gene, Ltd. Transaction History

Bellevue Group Ag

$5.02 Billion
Q4 2024

A detailed history of Bellevue Group Ag transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Bellevue Group Ag holds 34,229 shares of BGNE stock, worth $7.76 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

34,229

Previous 58,729 41.72%

Holding current value

$7.76 Million

Previous $13.2 Million 52.05%

% of portfolio

0.13%

Previous 0.22%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$174.72 - $246.04 $4.28 Million - $6.03 Million	-24,500 Reduced 41.72%	34,229 $6.32 Million
Q3 2024 Nov 14, 2024	BUY	$143.93 - $224.51 $4.76 Million - $7.43 Million	33,100 Added 129.15%	58,729 $13.2 Million
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $90,664 - $122,024	700 Added 2.81%	25,629 $3.66 Million
Q1 2024 May 15, 2024	SELL	$141.8 - $181.47 $520,547 - $666,176	-3,671 Reduced 12.84%	24,929 $3.9 Million
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $3.9 Million - $4.96 Million	-24,600 Reduced 46.24%	28,600 $5.16 Million
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $7.73 Million - $9.68 Million	43,000 Added 421.57%	53,200 $9.57 Million
Q2 2023 Aug 14, 2023	SELL	$178.3 - $266.78 $8.56 Million - $12.8 Million	-48,035 Reduced 82.48%	10,200 $1.82 Million
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $5.12 Million - $6.52 Million	23,735 Added 68.8%	58,235 $12.6 Million
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $3.45 Million - $6.31 Million	27,500 Added 392.86%	34,500 $7.59 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $922,600 - $1.42 Million	7,000 New	7,000 $940,000
Q1 2022 May 13, 2022	SELL	$146.52 - $269.56 $3.37 Million - $6.2 Million	-23,000 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$249.6 - $403.14 $15.3 Million - $24.7 Million	-61,300 Reduced 72.72%	23,000 $8.35 Million
Q2 2021 Aug 12, 2021	BUY	$292.75 - $367.01 $7.2 Million - $9.03 Million	24,600 Added 41.21%	84,300 $28.9 Million
Q1 2021 May 12, 2021	SELL	$260.64 - $382.12 $12.4 Million - $18.1 Million	-47,400 Reduced 44.26%	59,700 $20.8 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $15 Million - $21.4 Million	67,700 Added 171.83%	107,100 $27.7 Million
Q3 2020 Nov 16, 2020	SELL	$189.18 - $286.44 $3.52 Million - $5.33 Million	-18,600 Reduced 32.07%	39,400 $11.3 Million
Q2 2020 Aug 13, 2020	SELL	$123.9 - $195.41 $61,950 - $97,705	-500 Reduced 0.85%	58,000 $10.9 Million
Q1 2020 May 14, 2020	BUY	$121.84 - $173.19 $1.42 Million - $2.02 Million	11,644 Added 24.85%	58,500 $7.2 Million
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $2.92 Million - $5.26 Million	-25,244 Reduced 35.01%	46,856 $7.77 Million
Q3 2019 Nov 14, 2019	SELL	$120.61 - $148.29 $2.52 Million - $3.1 Million	-20,900 Reduced 22.47%	72,100 $8.98 Million
Q2 2019 Aug 14, 2019	SELL	$113.99 - $146.86 $1.05 Million - $1.35 Million	-9,200 Reduced 9.0%	93,000 $11.5 Million
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $2.28 Million - $2.82 Million	18,600 Added 22.25%	102,200 $13.5 Million
Q4 2018 Feb 12, 2019	BUY	$107.01 - $175.15 $7.7 Million - $12.6 Million	71,980 Added 619.45%	83,600 $11.7 Million
Q3 2018 Nov 13, 2018	BUY	$152.62 - $189.66 $18,314 - $22,759	120 Added 1.04%	11,620 $2 Million
Q2 2018 Aug 07, 2018	SELL	$152.5 - $216.77 $4.45 Million - $6.32 Million	-29,150 Reduced 71.71%	11,500 $1.77 Million
Q1 2018 May 09, 2018	SELL	$97.41 - $177.22 $6.14 Million - $11.2 Million	-63,000 Reduced 60.78%	40,650 $6.83 Million
Q4 2017 Feb 14, 2018	BUY	$79.6 - $114.73 $8.25 Million - $11.9 Million	103,650	103,650 $10.1 Million

Others Institutions Holding BGNE

# of Institutions

254

Shares Held

45.1M

Call Options Held

131K

Put Options Held

95.6K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Bei Gene, Ltd. Transaction History